Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit
Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for cancer, will participate in the TD Cowen 5th Annual Oncology Innovation Summit on May 28, 2024, at 10:30 a.m. ET.
The event will be virtual, featuring a fireside chat with the management team. A live webcast and archived recording will be available on the company's website.
- Participation in a high-profile oncology summit can increase visibility and credibility.
- Virtual fireside chat allows broader access to insights from the management team.
- Availability of live webcast and archived recording enhances investor engagement.
- The announcement lacks new clinical or financial data impacting immediate stock performance.
- No new product developments or partnerships were disclosed.
- Virtual format may be less impactful compared to in-person events.
NEW YORK and SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that members of the management team will participate in a virtual fireside chat during the TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO and EHA on May 28, 2024 at 10:30 a.m. ET.
Access to a live webcast of this event, as well as an archived recording, will be available under the “Events & Presentations” tab on the Investors & Media section of the Company’s website.
About Zentalis Pharmaceuticals
Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate, azenosertib (ZN-c3), is a potentially first-in-class and best-in-class WEE1 inhibitor for advanced solid tumors and hematologic malignancies. Azenosertib is being evaluated as a monotherapy and in combination across multiple clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types and in combination with several chemotherapy backbones. As part of its azenosertib clinical development program, the Company is exploring enrichment strategies targeting tumors of high genomic instability, such as Cyclin E1 positive tumors, homologous recombination deficient tumors and tumors with oncogenic driver mutations. The Company is also leveraging its extensive experience and capabilities across cancer biology and medicinal chemistry to advance its research on protein degraders. Zentalis has operations in both New York and San Diego.
For more information, please visit www.zentalis.com. Follow Zentalis on X (Twitter) @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals. ZENTALIS® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release.
Contact:
Elizabeth Pingpank Hickin
ehickin@zentalis.com
860-463-0469
FAQ
What event is Zentalis Pharmaceuticals participating in?
When is the Zentalis Pharmaceuticals virtual fireside chat?
Where can I access the Zentalis Pharmaceuticals fireside chat webcast?
What is the focus of Zentalis Pharmaceuticals?
What is the stock symbol for Zentalis Pharmaceuticals?
